236 related articles for article (PubMed ID: 28569545)
1. Interview with Alexander Cohen.
Cohen AA
Future Cardiol; 2017 May; 13(3):207-209. PubMed ID: 28569545
[TBL] [Abstract][Full Text] [Related]
2. A vascular physician's view of venous thromboembolism and apixaban.
Cohen A; Wu WH
Future Cardiol; 2014 Nov; 10(6):679-81. PubMed ID: 25495808
[TBL] [Abstract][Full Text] [Related]
3. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
4. Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness.
Tomkowski WZ; Davidson BL
Thromb Res; 2019 Aug; 180():62-63. PubMed ID: 31226663
[No Abstract] [Full Text] [Related]
5. Uses of the Twins UK genetic database.
Spector TD
Per Med; 2007 Nov; 4(4):457-461. PubMed ID: 29793272
[TBL] [Abstract][Full Text] [Related]
6. Interview: Key questions in pain research: clinical observations informing research and vice versa.
Bennett D
Pain Manag; 2011 Mar; 1(2):123-5. PubMed ID: 24646353
[TBL] [Abstract][Full Text] [Related]
7. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
8. [The EINSTEIN CHOICE study].
Agnelli G; Becattini C; Giustozzi M; Imberti D; Benedetti R; Fontana M
G Ital Cardiol (Rome); 2017 Sep; 18(9):613-617. PubMed ID: 28845870
[No Abstract] [Full Text] [Related]
9. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
10. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
11. Purinergic signaling in the gastrointestinal tract.
Burnstock G
World J Gastrointest Pathophysiol; 2011 Apr; 2(2):31-4. PubMed ID: 21607164
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
13. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
[TBL] [Abstract][Full Text] [Related]
14. [Use of rivaroxaban in real-life treatment of venous thromboembolism: results of the TEV Survey, an Italian epidemiological study].
Pesavento R; Iori I;
G Ital Cardiol (Rome); 2017 Mar; 18(3):239-246. PubMed ID: 28398382
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
16. Interview: partnering with the industry: the Olympic laboratory model.
Cowan DA; Barker CP
Bioanalysis; 2012 Jul; 4(13):1545-8. PubMed ID: 22831471
[TBL] [Abstract][Full Text] [Related]
17. A profile of Keith AA Fox, cardiologist and researcher.
Fox KA; Telfer C
Future Cardiol; 2014 Jan; 10(1):27-9. PubMed ID: 24344658
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
20. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
